Skip to main content
Premium Trial:

Request an Annual Quote

Matrix-Bio Options Purdue Technologies for Cancer Dx Development

NEW YORK (GenomeWeb News) – Metabolite-based diagnostic firm Matrix-Bio announced today it has signed an exclusive agreement with the Purdue Research Foundation to potentially develop cancer diagnostic tests based on Purdue University's technologies.

Matrix-Bio is optioning metabolite biomarker technology and eight patent applications as part of the deal in order to assess the commercial potential of tests based on the technologies. The technologies include metabolite biomarkers for the detection of esophageal, liver, pancreatic, and colon cancer; biomarkers for identifying liver cancer in hepatitis C patients; and biomarkers for predicting pre-operative chemotherapy effectiveness for breast cancer treatment.

The deal is for one year with an option to extend it. No further details were disclosed.

Today's deal builds on a master licensing agreement between the Fort Wayne, Ind.-based company and Purdue Research Foundation for breast cancer biomarkers and metabolite profiling technology that was developed by the company's founder and CSO, Dan Raftery, while he was at Purdue. He is now director of the Northwest Metabolomics Research Center at the University of Washington and a member of the Fred Hutchinson Cancer Research Center.

The agreement, Matrix-Bio CEO Eric Beier, said in a statement, "will enable the company to significantly expand its pipeline of detection and monitoring tests, further advancing the company's leadership in metabolomics-based cancer diagnostic technologies."

Its technology platform combines mass spectrometry and nuclear magnetic resonance to identify biomarkers that may be associated with early stage breast cancer and recurrence post-therapy.

In April, Matrix-Bio reached a deal with Quest Diagnostics for the use of metabolomic biomarkers in developing a breast cancer recurrence test.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.